pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 1 · small molecule · peritonitis
This program represents a Phase 1 intraperitoneal combination therapy for multi-quadrant peritonitis, sponsored by Lacuna Pharma Pty Ltd. The investigational treatment combines fosfomycin (a broad-spectrum antibiotic), metronidazole (an antimicrobial agent), and recombinant human granulocyte-macrophage colony-stimulati
Internal code 2025-GMF-1
This program represents a Phase 1 intraperitoneal combination therapy for multi-quadrant peritonitis, sponsored by Lacuna Pharma Pty Ltd. The investigational treatment combines fosfomycin (a broad-spectrum antibiotic), metronidazole (an antimicrobial agent), and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) administered directly into the peritoneal cavity during abdominal surgery. The TRIPLE trial is a randomized, placebo-controlled study evaluating this triple-agent approach in patients with severe peritonitis requiring surgical intervention. As a Phase 1 program, the trial is currently in early-stage clinical development, with the primary focus on safety, tolerability, and preliminary efficacy assessment. The intraperitoneal route of administration allows for high local drug concentrations at the infection site while potentially minimizing systemic exposure. Regulatory status across major jurisdictions remains not yet disclosed; the program is identified as active in clinical trials with NCT identifier 2024-520317-49-02.
Peritonitis, particularly multi-quadrant peritonitis requiring surgical intervention, represents a serious medical emergency with significant morbidity and mortality despite current standard-of-care antibiotics. The unmet medical need centers on improving outcomes in patients with complex, diffuse intra-abdominal infections where conventional systemic antibiotic therapy may be insufficient. The combination approach—pairing antimicrobials with an immunomodulatory agent (rhGM-CSF)—addresses both pathogen elimination and host immune response, potentially offering a mechanistic advantage over antibiotics alone. The intraperitoneal delivery strategy is clinically relevant because it achieves high local concentrations of active agents directly at the infection site, which may improve efficacy while reducing systemic toxicity. The patient population includes surgical patients with severe peritonitis, a population with limited therapeutic options and high clinical need. Commercial significance is tied to the potential for a differentiated treatment approach in a serious infection indication, though the Phase 1 stage indicates early development. Success in this program could establish a new paradigm for intra-abdominal infection management, particularly in the perioperative setting.
Drug Class: Combination antimicrobial and immunomodulatory therapy
Modality: Small molecule (fosfomycin, metronidazole) plus biologic (recombinant human granulocyte-macrophage colony-stimulating factor)
Route of Administration: Intraperitoneal (direct instillation during abdominal surgery)
Components:
Indication: Multi-quadrant peritonitis in patients undergoing abdominal surgery
Related Therapies: Systemic antibiotic regimens (standard of care); intraperitoneal antibiotic lavage (established surgical practice)
Patent Status: Not yet disclosed
First Approval: Not yet disclosed; program is in Phase 1 clinical development
Also known as: peritoneum inflammation
Inflammation of the peritoneum (tissue that lines the abdominal wall and covers most of the organs in the abdomen).
ClinicalTrials.gov lists 68 registered studies for Peritonitis (AACT aggregate).
Phase breakdown: NA (49), PHASE4 (9), PHASE3 (7), PHASE2 (2), PHASE1 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:1010128), NCT00001224, NCT00001256, NCT00001351, NCT00001415, NCT00001541, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, NCT00131196, NCT00173485, NCT00195351, NCT00210938, NCT00229060 (CC BY 4.0).
TRIPLE Trial Ongoing
Randomized placebo-controlled Phase 1 trial of intraperitoneal fosfomycin, metronidazole, and rhGM-CSF in multi-quadrant peritonitis patients undergoing abdominal surgery.
The competitive landscape for peritonitis treatment includes both systemic and local antimicrobial approaches. Within the facts provided, a competing program is identified: METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi 9 mg/ml solution for infusion, and FOSFOMYCIN, also sponsored by Lacuna Pharma Pty Ltd and currently in Phase 1 status. This suggests the sponsor may be evaluating multiple formulation or delivery strategies for similar agent combinations. Other competitors noted include Cholecalciferol (approved status, small molecule, from The First People's Hospital of Lianyungang) and Co-Trimoxazole 960Mg Dispersible Tablet (Phase 3, small molecule, from United Therapeutics Europe Ltd), though these appear to address different therapeutic areas or indications and are not direct comparators for peritonitis treatment. The TRIPLE trial's differentiation lies in its combination of targeted antimicrobials with immunomodulation via rhGM-CSF, delivered intraperitoneal during surgery—a mechanistic approach distinct from standard systemic antibiotic therapy. Competitive positioning will depend on Phase 1 safety and tolerability data, followed by efficacy signals in later-stage trials.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Cholecalciferol | The First People's Hospital of Lianyungang | small_molecule | approved |
| Co-Trimoxazole 960Mg Dispersible Tablet | United Therapeutics Europe Ltd | small_molecule | phase_3 |
| METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi 9 mg/ml solution for infusion, FOSFOMYCIN | Lacuna Pharma Pty Ltd | small_molecule | phase_1 |
FDA Status: Not yet disclosed
EMA Status: Not yet disclosed
PMDA (Japan) Status: Not yet disclosed
NMPA (China) Status: Clinical trials status identified via NCT identifiers; specific approval pathway or timeline not yet disclosed
Clinical Trial Registration: Program identified with NCT identifier 2024-520317-49-02, indicating active enrollment in clinical trial registry. Additional related NCT identifiers are referenced in the drug components (NCT01719640, NCT05543330, NCT03720340, NCT05105685, NCT06220929, NCT06920576, NCT03180944, NCT03423797, NCT06157918, NCT06353334, NCT07084350), though their direct relationship to the TRIPLE trial requires clarification.
Regulatory Pathway: Not yet disclosed. Phase 1 status suggests early-stage IND/clinical trial authorization has been obtained, but specific regulatory jurisdiction and approval strategy remain undisclosed.
The TRIPLE trial is a randomized, placebo-controlled Phase 1 study evaluating intraperitoneal treatment with fosfomycin, metronidazole, and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery.
The indication is peritonitis, specifically multi-quadrant peritonitis in patients requiring abdominal surgery.
Lacuna Pharma Pty Ltd is the sponsor of the TRIPLE trial and related programs.
The program is currently in Phase 1 clinical development.
The investigational therapy is administered intraperitoneal (directly into the peritoneal cavity) during abdominal surgery.
The treatment combines fosfomycin (broad-spectrum antibiotic), metronidazole (antimicrobial agent), and recombinant human granulocyte-macrophage colony-stimulating factor (immunomodulatory cytokine).
Intraperitoneal delivery concentrates active agents directly at the infection site in the peritoneal cavity, potentially achieving higher local drug concentrations while reducing systemic exposure compared to systemic antibiotic therapy.
rhGM-CSF is an immunomodulatory cytokine included to potentially enhance host immune response and improve clinical outcomes beyond antimicrobial activity alone.
Regulatory approval status is not yet disclosed; the program is currently in Phase 1 clinical trials.
The primary clinical trial identifier is 2024-520317-49-02; additional related NCT identifiers are referenced but their direct relationship to TRIPLE requires clarification.
The program combines small-molecule antimicrobials (fosfomycin and metronidazole) with a biologic immunomodulator (recombinant human granulocyte-macrophage colony-stimulating factor).
A related program by the same sponsor (METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi, FOSFOMYCIN) is also in Phase 1, suggesting portfolio exploration of formulation variants. Other competitors in infectious disease exist but are not direct comparators for peritonitis.
The patient population consists of individuals with multi-quadrant peritonitis who are undergoing abdominal surgery.
Primary endpoints are not yet disclosed; Phase 1 trials typically focus on safety, tolerability, and dose escalation.
Expected next milestone date and label are not yet disclosed.
Multi-quadrant peritonitis requiring surgery has significant morbidity and mortality despite current standard-of-care antibiotics; this program aims to improve outcomes through combination antimicrobial-immunomodulatory therapy delivered directly to the infection site.
2025-GMF-1 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Lacuna Pharma Pty Ltd's Phase 1 TRIPLE trial represents an early-stage exploration of combination antimicrobial-immunomodulatory therapy for a serious surgical infection indication. The intraperitoneal delivery approach is strategically sound, as it concentrates active agents at the site of infection while potentially reducing systemic exposure and toxicity. The inclusion of rhGM-CSF alongside antimicrobials suggests a hypothesis that immune augmentation may enhance clinical outcomes beyond antimicrobial monotherapy.
Competitive Implications: The sponsor's parallel development of a related combination therapy (METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi, FOSFOMYCIN) in Phase 1 indicates portfolio exploration of formulation or delivery variants. Success of either program could establish a differentiated approach in peritonitis management. However, the Phase 1 stage means efficacy and safety data remain preliminary; competitive positioning will crystallize only after Phase 2 data emerge.
Future Catalysts: Key milestones include Phase 1 safety and tolerability readout, determination of optimal dosing and administration timing, and progression to Phase 2 efficacy trials. Regulatory feedback on the clinical trial design and endpoints will influence development trajectory. Publication of Phase 1 results in peer-reviewed journals would provide transparency and inform clinical community engagement.
Expected Milestones: Phase 1 completion and safety summary; Phase 2 initiation (if warranted); preliminary efficacy signals in peritonitis outcomes (infection resolution, mortality, morbidity reduction). Timelines for these milestones are not yet disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.